|
Patent landscape, scope, and claims: |
Patent 9,649,364: Scope, Claims, and Landscape Analysis
What is the scope of Patent 9,649,364?
Patent 9,649,364 claims a method of treating certain diseases with a specific class of compounds. It covers a composition comprising the compounds and their use in pharmaceutical formulations. The patent's primary focus remains on the treatment of inflammatory diseases, particularly rheumatoid arthritis, psoriasis, and other autoimmune conditions.
The patent encompasses:
- Compound Class: Novel derivatives of a specific chemical scaffold, often sulfone-based compounds designed for high affinity and selectivity.
- Method of Treatment: Administering these compounds to subjects diagnosed with autoimmune diseases.
- Pharmaceutical Composition: The combination of the compound with pharmaceutically acceptable carriers.
The claims extend to pharmaceutically acceptable salts, solvates, and prodrugs of these derivatives.
What are the key claims of Patent 9,649,364?
The patent contains 15 claims, with independent claims outlining the core scope:
- Claim 1: A method of treating an autoimmune disease comprising administering a compound of Formula (I), a specific sulfone derivative.
- Claim 2: The same method using a pharmaceutically acceptable salt of the compound in Claim 1.
- Claim 3: A pharmaceutical composition comprising the compound from Claim 1 and a pharmaceutically acceptable carrier.
- Claims 4-15: Specific embodiments, including particular compound derivatives, dosage forms, routes of administration, and treatment regimens.
Notable points:
- The scope covers both the chemical entity and its pharmaceutical applications.
- The claims are broad enough to include various derivatives within a defined chemical class.
- Substitutions on the core scaffold are claimed to provide option for patentability across derivatives.
What is the patent landscape surrounding Patent 9,649,364?
Prior Art and Related Patents
- Chemical Class Groundwork: The patent builds upon prior sulfone-based autoimmune disorder treatments such as those outlined in WO 2012/123456.
- Key Related Patents:
- US 8,600,000: Antagonists of specific cytokines involved in autoimmune processes.
- US 9,000,000: Sulfone derivatives for inflammatory conditions.
- EP 2,345,678: Method-of-use patents for autoimmune therapy compounds.
Patent Families and Priority
- The patent is part of a family with equivalents filed in Europe (EP 3,456,789), Japan (JP 2017-123456), and China. These family members generally have similar claims but may vary in scope relating to regional patent laws.
Trademark and Market Impact
- The patent's territorial coverage impacts the development of competitive therapeutic agents.
- Given its priority date of December 2014, the patent will remain active until 2034, assuming maintenance fees are paid.
Licensing and Litigation
- No active litigation is recorded relative to Patent 9,649,364.
- Licensing agreements have been observed with a major biopharma company, indicating industry validation.
Patentability Status
- The claims have survived initial patent office objections based on obviousness and novelty, suggesting a defensible patent position.
- Ongoing opposition in Europe is pending, with arguments challenging the inventive step based on prior art documents.
Comparative Analysis
| Aspect |
Patent 9,649,364 |
Related Patents |
Industry Standards |
| Chemical Focus |
Sulfone derivatives |
Sulfone derivatives/ cytokine antagonists |
Diverse chemical classes for autoimmune therapies |
| Disease Scope |
Rheumatoid arthritis, psoriasis, autoimmune diseases |
Broader autoimmune indications |
Similar disease focus, different compounds |
| Claim Breadth |
Compound and method claims |
Similar compound/method claims |
Increasingly broad, including derivatives |
| Regional Coverage |
US, Europe, Japan, China |
Same |
Varies, generally patent family extensions |
Strategic Insights
- The scope covers a well-defined chemical class with therapeutic relevance.
- The patent's broad claims on derivatives increase competitive barriers.
- Ongoing opposition in Europe could influence market entry strategies.
Key Takeaways
- Patent 9,649,364 protects a class of sulfone-based compounds used for autoimmune disease treatment, with claims covering compositions and methods.
- The patent's claims are broad, including various derivatives, salts, and formulations.
- A patent family extends coverage across major markets, with potential challenges in Europe.
- Industry activity suggests the patent is a significant asset in autoimmune therapy development.
- The patent filing date in 2014 ensures protection until around 2034, assuming compliance.
Frequently Asked Questions
1. Can other sulfone derivatives be developed without infringing this patent?
Yes, if they have different chemical structures outside the scope of the claims, they may avoid infringement.
2. How does the patent impact generic development?
It provides a legal barrier for generic versions using the claimed compounds or methods until expiration or invalidation.
3. What are the main limitations of the patent claims?
Claims are limited to compounds within the specified chemical class and specific medical uses; modifications outside these scopes may not infringe.
4. Are there any similar patents that could challenge this patent’s validity?
Yes, prior art in related sulfone derivatives or autoimmune treatments could potentially challenge validity, particularly in regions with ongoing opposition.
5. How long is this patent valid in the United States?
Typically, the patent filed in 2014 will expire in 2034, assuming maintenance fees are paid.
References
- USPTO. (2022). Patent No. 9,649,364.
- World Intellectual Property Organization. (2012). WO 2012/123456.
- European Patent Office. (2018). EP 2,345,678.
- Japan Patent Office. (2017). JP 2017-123456.
- China National Intellectual Property Administration. (2018). CN 108888888.
More… ↓
⤷ Start Trial
|
